NXS 4.44% 23.5¢ next science limited

Ann: Next Science US Medicare accreditation signals growth, page-9

  1. 4,317 Posts.
    lightbulb Created with Sketch. 725
    Interesting- The Surgeon is correct in that many big claims are made by many. The Proof is far more interesting given the US hospital roll out I and the still large single to double digit post surgical complication by avoidable wound infections where Best Practice is not considered would be a legal quagmire I think for ignorance of the actual evidence.

    Noting there is a low priority for Bactisure™ Wound Lavage and XPERIENCE here while the big money markets are prioritizes.


    IF we had actual data on the Surgerys that surgeon had preformed and the number of post Surgical infections, the cost to the patients and the cost to the Hospital/ Health insurance funds - I suspect it would be fairly easy to ask the surgeon to consider those two preventative products or do as I would and find a smarter surgeon.


 
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.010(4.44%)
Mkt cap ! $68.54M
Open High Low Value Volume
22.0¢ 23.5¢ 21.5¢ $46.14K 206.3K

Buyers (Bids)

No. Vol. Price($)
4 130676 21.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 19533 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
NXS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.